NBDA Convergence Conferences
Consensus conferences (which date from the 1980's) in biomedical research are generally held to systematically arrive at “consensus” on foundational scientific elements or policies that underlie a specific area/body of science. Undoubtedly, these meetings have great value, but often the results are never implemented or accepted. The NBDA is taking a new and different approach through its “Convergence Conferences”. The overall goal of these Conferences is two-fold: to converge on the “standards” that the technical communities agree have necessary and sufficient evidentiary support that they should at a minimum be employed as recommended; and to include stakeholders beyond the technical communities that can converge on the best approaches and possible models to achieve a high level of compliance with recommended standards.
NBDA will from time convene such “Convergence Conferences” to enable the representatives stakeholders from the biomarker communities to reach agreement on the most appropriate technical "standards" to support a specific aspect of biomarker research and development; and to focus on the messaging and approaches that can be most effective in implementing these convergent “standards”.
Areas where NBDA Convergence Conferences will be convened by the NBDA in the next several months include: standards for biospecimens to support biomarker research and development (R&D), specifically targeted to nucleic acid and proteomic biomarkers; and imaging biomarkers (specifically MRI) for use in selected clinical trials.
Convergence Conference: Biospecimen Standards for Genomic Biomarkers Analyzed by NGS
Convergence Conference: Biospecimen Standards for Proteomic Biomarkers Analyzed by Mass Spectrometry
Convergence Conference: Standards for Biomarker Measurement using Diffusion Weighted MRI
*NBDA Standards includes but is not limited to: “official existing standards”, guidelines, principals, standard operating procedures (SOP), and best practices.